FDA approves new drug for schizophrenia, major depression

July 13, 2015

U.S. FDA approves new drug for schizophrenia, major depression
Medication can be used as an add-on therapy to antidepressants.
(HealthDay)—A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration.

Rexulti (brexpiprazole) tablets can be used to treat adults with . The new drug can also be used as an add-on therapy to for adults with .

"Schizophrenia and can be disabling and can greatly disrupt day-to-day activities," Dr. Mitchell Mathis, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Medications affect everyone differently so it is important to have a variety of treatment options available for patients with mental illnesses," he added.

The FDA's approval of Rexulti for treatment of schizophrenia is based on two six-week clinical trials with more than 1,300 people. People taking the drug had fewer symptoms of schizophrenia than those who took a placebo, the studies found.

Rexulti was also tested as an add-on therapy for major depression. For this treatment, researchers conducted two six-week clinical trials. The trials included more than 1,000 patients whose symptoms were not adequately treated by taking an antidepressant alone. Those who took Rexulti and an antidepressant had fewer symptoms of depression than those who took a placebo and an antidepressant, the FDA said.

Weight gain and a sense of restlessness were the most common side effects reported by patients taking Rexulti. The drug is made by Otsuka Pharmaceutical Company Ltd. in Japan.

Like other , Rexulti has a boxed warning about an increased risk of death associated with unapproved use of the drugs to treat behavioral problems in people with dementia-related psychosis.

The boxed warning also cautions about an increased risk of and behavior in children, teens and young adults taking antidepressants. People taking the drug should be monitored for the start or worsening of suicidal thoughts and behavior, the FDA said.

Explore further: First generic Abilify approved

More information: The U.S. National Institute of Mental Health has more about schizophrenia.

Related Stories

First generic Abilify approved

April 30, 2015
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

Brintellix approved for major depressive disorder

October 1, 2013
(HealthDay)—Brintellix (vortioxetine) has been approved by the U.S. Food and Drug Administration to treat adults with major depressive disorder, often referred to as depression.

FDA approves new drugs for irritable bowel syndrome

May 28, 2015
(HealthDay)—Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday.

Antidepressant-suicide link in youths absent in new analysis

February 6, 2012
In 2004, concerns about antidepressant drugs increasing suicidal thoughts and behaviors in young patients prompted the FDA to issue a rare "black box warning." Now, a new analysis of clinical trial data finds that treatment ...

FDA OKs new anti-clotting drug for heart rhythm disorder

January 9, 2015
(HealthDay)—A new anti-clotting drug to reduce the risk of dangerous blood clots and strokes in people with a type of heart rhythm disorder has been approved by the U.S. Food and Drug Administration.

FDA weighs removing bolded warning from Chantix

October 14, 2014
(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.